CMMB Q2 2024 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$26,901

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-1.01

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$15M

Total Liabilities

$5M

Stockholders' Equity

$10M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$26,901	-$15,818	-70.1%
Operating Income	-$4M	-$8M	+54.0%
Net Income	-$4M	-$8M	+54.4%